Trump's deal slashes GLP-1 drug costs for Medicare beneficiaries and others, unlocking coverage for millions with obesity and ...

Novo Nordisk (NYSE: NVO) has announced sweeping price cuts for its blockbuster GLP-1 drugs, Wegovy and Ozempic, offering ...

The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.

Novo Nordisk A/S is undercutting arch-rival Eli Lilly & Co. on obesity drugs for cash-pay patients, showing its willingness ...

Medicare coverage will cut obesity-drug prices but open the door to millions of new patients.

Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have ...

The weight loss medicines are proving to be a test case for Robert F. Kennedy Jr., the health secretary, in straddling ...

Medicare will cover GLP-1 weight loss drugs for specific patient groups, beginning in mid-2026, under a deal struck with drugmakers.

"Developing new ways to treat these patients is of the utmost importance," Dr. Casey H. Halpern, a senior author of the study ...

The Trump administration struck deals with pharmaceutical companies Novo Nordisk and Eli Lilly to lower prices and copays for ...

The list prices of obesity drugs Wegovy and Zepbound are over $1,000, but that’s not necessarily what you pay.

Pfizer noted it has completed its acquisition of all outstanding shares of the company’s common stock for $65.60 per share in ...